Dr. Gordon Shore
Rosalind and Morris Goodman Cancer Research Centre
Department of Biochemistry
Bcl-2 Family Proteins and Cancer
In This family of opposing cell survival and cell death proteins regulates pathways associated with apoptotic and non-apoptotic forms of cell death, as well as cellular macroautophagy – all of which are critical for both normal development and various pathologies, including many forms of cancer. Family members reside primarily at mitochondria and ER, where they regulate key structural and functional activities of these organelles, as well as important inter-organellar dynamics. Our lab studies various aspects of this complex and unique biology, including the modulation of Bcl-2 family activity for potential therapeutic benefit in cancer.
Laboratory for Therapeutic Development
Exploiting genome-wide screens and the principles of synthetic lethality and personalized medicine, our goal is to generate the underlying knowledge about drugs and targets that supports rational strategies for clinical proof-of-concept studies in oncology. This “Integrated Platform” attempts to generate the knowledge to predict rational drug combination, patient stratification, and biomarker strategies in support of the PoC study – all within the existing regulatory, clinical practice and limiting toxicology frameworks.
Funding: Canadian Institutes of Health Research (CIHR); Le Consortium québécois sur la découverte du médicament (CQDM); Génome Québec.
PLEASE NOTE: We currently seek highly qualified individuals for Postdoctoral positions.